"Aminobutyrates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivatives of BUTYRIC ACID that contain one or more amino groups attached to the aliphatic structure. Included under this heading are a broad variety of acid forms, salts, esters, and amides that include the aminobutryrate structure.
| Descriptor ID |
D000613
|
| MeSH Number(s) |
D02.241.081.114.500 D12.125.190
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aminobutyrates".
Below are MeSH descriptors whose meaning is more specific than "Aminobutyrates".
This graph shows the total number of publications written about "Aminobutyrates" by people in this website by year, and whether "Aminobutyrates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 18 | 8 | 26 |
| 2018 | 15 | 5 | 20 |
| 2019 | 8 | 4 | 12 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Aminobutyrates" by people in Profiles.
-
Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. Med Hypotheses. 2021 Feb; 147:110486.
-
The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19. Int J Mol Sci. 2020 Nov 15; 21(22).
-
[Impact of the COVID-19 pandemic on the management of heart failure outpatient clinics. Lessons during the lockdown restrictions]. G Ital Cardiol (Rome). 2020 Oct; 21(10):750-756.
-
Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients. Eur Heart J Cardiovasc Pharmacother. 2020 07 01; 6(3):135-136.
-
Sacubitril/valsartan in COVID-19 patients: the need for trials. Eur Heart J Cardiovasc Pharmacother. 2020 07 01; 6(4):253-254.
-
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. JACC Heart Fail. 2020 10; 8(10):789-799.
-
Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. Eur Heart J. 2019 10 21; 40(40):3345-3352.
-
Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. Circulation. 2019 10 22; 140(17):1369-1379.
-
Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2019 11; 7(11):933-941.
-
Emerging Drug Classes and Their Potential Use in Hypertension. Hypertension. 2019 11; 74(5):1075-1083.